In vitro analysis of new putative biomarkers for OCT2/MATE-mediated renal drug-drug interactions

被引：0
|
作者：
Picurova, J. [1 ]
Mueller, F. [1 ,2 ]
Koenig, J. [1 ]
Stopfer, P. [1 ]
Fromm, M. F. [1 ]
Gessner, A. [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Numberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P075
引用
收藏
页码：S35 / S36
页数：2
相关论文
共 50 条
  • [31] IN VITRO TO IN VIVO TRANSLATION OF OATP-MEDIATED DRUG-DRUG INTERACTIONS IN CYNOMOLGUS MONKEY
    Ufuk, Ayse
    Kosa, Rachel E.
    Gao, Hongying
    Bi, Yi-An
    Modi, Sweta
    Rodrigues, A. David
    Tremaine, Larry
    Varma, Manthena V.
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S16 - S16
  • [32] Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions
    Willemin, Marie-Emilie
    Van der Made, Thomas K.
    Pijpers, Ils
    Dillen, Lieve
    Kunze, Annett
    Jonkers, Sophie
    Steemans, Kathleen
    Tuytelaars, An
    Jacobs, Frank
    Monshouwer, Mario
    Scotcher, Daniel
    Rostami-Hodjegan, Amin
    Galetin, Aleksandra
    Snoeys, Jan
    CLINICAL PHARMACOKINETICS, 2021, 60 (09) : 1187 - 1199
  • [33] A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2-and MATE1-Mediated Transport of Metformin in Healthy Participants
    Bhardwaj, Rajinder
    Morris, Beth
    Matschke, Kyle
    Bertz, Richard
    Croop, Robert
    Liu, Jing
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (05): : 465 - 473
  • [34] Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin
    Sauzay, C.
    White-Koning, M.
    Hennebelle, I.
    Deluche, T.
    Delmas, C.
    Imbs, D. C.
    Chatelut, E.
    Thomas, F.
    PHARMACOLOGICAL RESEARCH, 2016, 110 : 89 - 95
  • [35] Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia
    Nishizawa, Kei
    Yoda, Noriaki
    Morokado, Fumi
    Komori, Hisakazu
    Nakanishi, Takeo
    Tamai, Ikumi
    PLOS ONE, 2019, 14 (04):
  • [36] Insights into CYP2B6-mediated drug-drug interactions
    Hedrich, William D.
    Hassan, Hazem E.
    Wang, Hongbing
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 413 - 425
  • [37] Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions
    Umehara, K. -I.
    Iwatsubo, T.
    Noguchi, K.
    Usui, T.
    Kamimura, H.
    XENOBIOTICA, 2008, 38 (09) : 1203 - 1218
  • [38] IN VITRO AND IN VIVO POTENTIAL OF ZURANOLONE TO CAUSE CYP-MEDIATED DRUG-DRUG INTERACTIONS.
    Dunbar, J.
    Srinivas, N.
    Hoffmann, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S36 - S36
  • [39] A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers
    Shen, Hong
    BIOANALYSIS, 2018, 10 (09) : 625 - 631
  • [40] Using Endogenous Biomarkers to Derisk Assessment of Transporter-Mediated Drug-Drug Interactions: A Scientific Perspective
    Arya, Vikram
    Reynolds, Kellie S.
    Yang, Xinning
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (12): : 1501 - 1506
12345